[go: up one dir, main page]

AR004752A1 - 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion. - Google Patents

2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.

Info

Publication number
AR004752A1
AR004752A1 ARP960105319A ARP960105319A AR004752A1 AR 004752 A1 AR004752 A1 AR 004752A1 AR P960105319 A ARP960105319 A AR P960105319A AR P960105319 A ARP960105319 A AR P960105319A AR 004752 A1 AR004752 A1 AR 004752A1
Authority
AR
Argentina
Prior art keywords
methyl
preparation
purin
imidazo
cyclopentane
Prior art date
Application number
ARP960105319A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR004752A1 publication Critical patent/AR004752A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de 2-[[4-halo-[1,1-bifenil]4-il]metil-5-metilespiro[ ciclopentano-1,7(8h)-[3h imidazo[2,1-b)purin]-4(5h)-onas, útiles comoantihipertensivos y broncodilatores de lafórmula (I) o su sal farmacéuticamente aceptable donde X es fluoro,cloro o bromo. Dichos compuestos seusan para lapreparación de un medicamento, además se describe una composición farmacéutica y el lproceso para su preparación.
ARP960105319A 1995-11-28 1996-11-25 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion. AR004752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56371795A 1995-11-28 1995-11-28

Publications (1)

Publication Number Publication Date
AR004752A1 true AR004752A1 (es) 1999-03-10

Family

ID=24251614

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105319A AR004752A1 (es) 1995-11-28 1996-11-25 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.

Country Status (8)

Country Link
EP (1) EP0863902A1 (es)
JP (1) JP2000501095A (es)
AR (1) AR004752A1 (es)
AU (1) AU1055597A (es)
CA (1) CA2237956A1 (es)
CO (1) CO4480029A1 (es)
WO (1) WO1997019947A1 (es)
ZA (1) ZA969888B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
WO2001047934A1 (de) 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Isoxazolopyrimidinone und ihre verwendung
CA2395548A1 (en) 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Imidazo 1,3,5 triazinones and the use thereof
WO2001047929A1 (de) 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Triazolotriazinone und ihre verwendung
MX2019007803A (es) 2016-12-28 2019-08-29 Dart Neuroscience Llc Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2).
DK3717488T3 (da) 2017-11-27 2021-12-13 Dart Neuroscience Llc Substituerede furanopyrimidinforbindelser som pde1-inhibitorer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
JPH08507068A (ja) * 1993-02-26 1996-07-30 シェリング・コーポレーション 2−ベンジル−多環式グアニン誘導体およびそれらの製造方法

Also Published As

Publication number Publication date
ZA969888B (en) 1997-05-26
JP2000501095A (ja) 2000-02-02
MX9804198A (es) 1998-10-31
WO1997019947A1 (en) 1997-06-05
CA2237956A1 (en) 1997-06-05
CO4480029A1 (es) 1997-07-09
AU1055597A (en) 1997-06-19
EP0863902A1 (en) 1998-09-16

Similar Documents

Publication Publication Date Title
AU3959693A (en) Alpha-aminoboronic acid peptides and their use as elastase inhibitors
TW262475B (en) Heterocyclic amides, intermediates and process for their preparation and pharmaceutical compositions containing them
GB9216272D0 (en) Substituted heterocycles
IL109526A0 (en) Benzofuranyl- and thiophenyl-alkanecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
DE69319238D1 (de) Lactampeptide mit hfl inhibierender aktivität
FI944802A (fi) HLE-proteiinien aktiivisuutta inhiboivat laktaamidipeptidit
FI944823A (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
AR004752A1 (es) 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.
HUT38097A (en) Process for preparing substituted benzopyrans and pharmaceutical compositions containing them as active substances
FI945696A0 (fi) Laktaamidipeptidejä, joilla on HLE:a inhiboiva aktiivisuus
DE3070847D1 (en) Benzazepine derivatives, process and intermediates for their preparation, their use and pharmaceutical compositions containing them
ATE171191T1 (de) Fluorenthaltende dipeptide als inhibitoren gegen elastase menschliches leukocyten
HUP9800512A2 (hu) Moenomicin csoportba tartozó antibiotikumok bizmutsói, eljárás előállításukra, ezek alkalmazása és ezeket tartalmazó gyógyszerkészítmények
DE3688087D1 (de) Cephemverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
ES2145740T3 (es) Composiciones de factor de crecimiento, preparacion y uso.
TH23729A (th) พิร์โรลิลเททระไฮโดรเบนโซควินอกแซลีนไดโอน การเตรียมและการใช้สารเหล่านั้น
TH24203A (th) อนุพันธ์ของออพทิคัลลี แอคทีฟ เบนโซไชอีพิน การเตรียมและการใช้ประโยชน์ของสารเหล่านี้